

A randomised double-blind placebo-controlled feasibility trial of flavonoid-rich cocoa for fatigue in people with relapsing and remitting multiple sclerosis

Coe, Shelly; Cossington, J; Collett, Johnny ; Soundy, Andrew; Izadi, H; Ovington , M; Durkin, L; Kirsten , M; Clegg, M; Wade, DT; Palace, J; DeLuca, G; Chapman, K; Harrison, J; Buckingham, E; Dawes, Helen

DOI:

[10.1136/jnnp-2018-319496](https://doi.org/10.1136/jnnp-2018-319496)

License:

Creative Commons: Attribution-NonCommercial (CC BY-NC)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Coe, S, Cossington, J, Collett, J, Soundy, A, Izadi, H, Ovington , M, Durkin, L, Kirsten , M, Clegg, M, Wade, DT, Palace, J, DeLuca, G, Chapman, K, Harrison, J, Buckingham, E & Dawes, H 2019, 'A randomised double-blind placebo-controlled feasibility trial of flavonoid-rich cocoa for fatigue in people with relapsing and remitting multiple sclerosis', *Journal of Neurology Neurosurgery and Psychiatry*, vol. 90, no. 5.
<https://doi.org/10.1136/jnnp-2018-319496>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Checked for eligibility: 25/03/2019

This article has been accepted for publication in *Journal of Neurology, Neurosurgery & Psychiatry* 2019, following peer review, and the Version of Record can be accessed online at: <http://dx.doi.org/10.1136/jnnp-2018-319926>

© Authors (or their employer(s)). Reuse of this manuscript version (excluding any databases, tables, diagrams, photographs and other images or illustrative material included where a another copyright owner is identified) is permitted strictly pursuant to the terms of the Creative Commons Attribution-Non Commercial 4.0 International (CC-BY-NC 4.0) <http://creativecommons.org>

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Title: A randomised double-blind placebo-controlled feasibility trial of flavonoid-rich cocoa for fatigue in people with Relapsing and Remitting Multiple Sclerosis.

Authors: Coe S.^{a*}, Cossington, J.^a, Collett J.^a, Soundy A.^b, Izadi H.^a, Ovington M.^a, Durkin L.^a, Kirsten M.^a, Clegg M.^d, Cavey A.^c, Wade DT.^a, Palace J.^c, DeLuca G.^c, Chapman K.^a, Harrison JM.^a, Buckingham E.^a & Dawes H.^a

*Corresponding author: Dr Shelly Coe, ^aCentre for Movement Occupational and Rehabilitation Sciences, Oxford Brookes Centre for Nutrition and Health, Department of Sport Health Sciences and Social Work, Oxford Brookes University, Oxford, OX30BP. Email: scoe@brookes.ac.uk, Tel: + (0)1865 483839. ^bUniversity of Birmingham, Birmingham. ^cDepartment of Neurology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DU, UK. Department of Food and Nutritional Sciences, University of Reading, Whiteknights, Reading RG6 6AP.

Key words

Fatigue, Cocoa, Diet, Multiple Sclerosis, Flavonoids

Word count: 3,335

References: 33

Abstract

The impact of flavonoids on fatigue has not been investigated in Relapsing and Remitting Multiple Sclerosis (RRMS).

Objective: To determine the feasibility and estimate the potential effect of flavonoid-rich cocoa on fatigue and fatigability in RRMS.

Methods: A randomised double-blind placebo-controlled feasibility study in people recently diagnosed with RRMS and fatigue, throughout the Thames Valley (ISRCTN: 69897291). During a six week intervention participants consumed a high or low flavonoid cocoa beverage daily. Fatigue and fatigability were measured at three visits (weeks 0, 3 and 6). Feasibility and fidelity were assessed through recruitment and retention, adherence and a process evaluation.

Results: 40 pwMS (10 men, 30 women, age 44 ± 10 yrs) were randomised and allocated to high (n=19) or low (n=21) flavonoid groups and included in analysis. Missing data was <20% and adherence to intervention of allocated individuals was >75%. There was a small effect on fatigue (Neuro-QoL: effect size {ES} 0.04; confidence interval {CI} -0.40-0.48) and a moderate effect on fatigability (six-minute walk test: ES 0.45; CI -0.18 - 1.07). There were seven adverse events (four control, three intervention), only one of which was possibly related and it was resolved.

Conclusion: A flavonoid beverage demonstrates the potential to improve fatigue and fatigability in RRMS.

Introduction

Ninety percent of people with Multiple Sclerosis (pwMS) experience fatigue [1]. Fatigue and fatigability are difficult to treat and greatly affect health related quality of life in pwMS [2]. Fatigability is a term derived from the broader definition of fatigue which refers to an inability to maintain both physical and cognitive performance [3]. The aetiology of fatigue in MS is complex including possible neural, inflammatory, metabolic and psychological mechanisms [2] [4]. Whilst a number of behavioural and drug approaches for fatigue management have been explored, to date the strongest evidence of success in reducing MS related fatigue is from exercise interventions [5] [6]. However success is limited and other approaches or combination therapies need to be investigated [7].

Dark chocolate containing 70-85% cocoa solids is well known for its high antioxidant and flavonoid content. Over a four week period, dark chocolate consumption has been shown to improve subjective fatigue in those with Chronic Fatigue Syndrome (CFS) [8] [9], and results from a small randomised controlled pilot study using a short-term cocoa intervention suggested an increase in sleep quality and reduction in fatigue [10]. A simple dietary supplement could be implemented alongside other behavioural interventions early after diagnosis as an adjunctive therapeutic approach to support pwMS to manage fatigue. There is currently limited evidence-based guidance to inform tailored dietary advice for symptom management in pwMS. Most diet based studies to date have looked at the risk of development or relapses in MS [11] [12]. However, modifiable lifestyle factors strongly correlate to clinically significant fatigue and remain a target for therapeutic trials [13]. To date there has been limited research assessing the effect of dietary interventions in pwMS [14], but they have identified good adherence to dietary interventions.

We propose that a flavonoid approach for managing MS related fatigue may be moderately effective, inexpensive, and safe [15] and that it may be exerting its effects by reducing inflammation and oxidative stress. The aim of the current trial was to evaluate the feasibility and estimate potential effect to inform a follow-on substantive trial. The following key objectives were assessed: 1) The acceptance of the study design and diet intervention by participants; 2) Monitoring recruitment rate and the process of randomisation, adherence to the protocol and loss to follow up; 3) Efficiency of data collection methods; 4) The estimate of effect size for fatigue, fatigability and other measures.

Methods

This was a parallel, randomised, double-blind placebo-controlled trial to assess feasibility and efficacy (Trial registration ISRCTN: 69897291; Ethical approval National Research Ethics Service {Solihull West Midlands} reference: 199515). Oxford Brookes University acted as sponsor and the study was conducted in accordance with the Declaration of Helsinki.

Recruitment

Recruitment was through neurology clinics in the Thames Valley, UK. In addition, local MS Society branches were made aware of the trial and given contact details, and an advertisement for the study along with the participant information sheet (PIS) was made available on the MS Society website. Individuals were able to self-refer to the study by contacting the researchers.

Setting

The intervention took place in the home of each participant. All testing took place at Oxford Brookes University (OBU), Oxford, UK except for optional home visits at week 3. Assessments took place between 7.30 and 10 am and the intervention lasted a total of 6 weeks with three testing visits (baseline, week 3 and 6).

Randomisation and allocation

After recruitment, participants were allocated the next available study number by the blinded assessor. The study number related to a computer-generated randomisation list held by the principle investigator and randomised individuals (1:1) into the intervention or the control group. The randomisation list used minimisation to balance groups for gender and if individuals were on disease modifying treatments (DMTs) at baseline. The list provided a three digit code that related to a code on identical pre-package sachets (made up by a co-investigator) containing either intervention or control cocoa. The sachets were then dispensed to the participant. The intervention began three days after baseline. Group allocation was concealed throughout the study and analysis.

Eligibility

Eligibility criteria were: adults aged ≥ 18 years with a < 10 year clinical diagnosis of RRMS, either treatment naïve or taking first line DMTs (supplementary file 1), no relapse or sudden change in MS symptoms within the previous three months, no contraindications to providing a blood sample or tolerating the cocoa drink, fatigue greater than 4 out of 7 on the Fatigue Severity Scale (FSS) [16], had no other conditions that may be associated with fatigue (e.g. anaemia), not on medication for the treatment of depression, an Expanded Disability Status Scale (EDSS) score of < 4.5 [17], sufficient mental capacity to consent, able to walk with or without a walker for at least 16 meters, no condition affecting the central nervous system other than MS (migraine and headache were allowed), not

pregnant or lactating and no objection to the researchers contacting their general practitioner (family doctor) and neurologist.

Intervention

Participants were provided with cocoa by the lead researcher at baseline and at week three, and they were asked to consume the drink in their homes daily. Cocoa was consumed after an overnight fast at the same time each morning. After the consumption of the drink, they were instructed to wait 30 minutes before consuming any other food or beverage and/ or take their medication. Participants were instructed to take their medication and to follow their usual diet for the rest of the day. The cocoa drinks (intervention and control) were designed to differ only in flavonoid content (low versus high flavonoid; supplementary file 2). Cocoa powder was provided to participants in air tight individual sachets. They were asked to add the sachet content to a mug and to add heated rice milk prior to consuming the drink. Instructions on preparation were provided to ensure all participants followed the same protocol. Unused cocoa powder was collected by the researcher at the next assessment.

Outcomes

The primary aim was to assess feasibility of the dietary intervention in terms of recruitment rate and the process of randomisation, adherence to the protocol and loss to follow up, safety and process. We documented adverse events (AEs). Duration of participation and dropout from the intervention were also recorded. Appropriateness of data collection methods was determined through completion of questionnaires and missing data, and through the process evaluation, and estimates of effect {effect sizes (ES) and confidence intervals (CI)} were calculated for the measures and demographics were collected at baseline.

Fatigue and fatigability

Throughout the six-week intervention participants were asked to rate their level of fatigue on a numerical rating scale (NRS) through daily 'fatigue texts' sent at 10:00, 15:00 and 20:00 every day, rating their fatigue between 1-10 (10 worst). They replied to the text message of '*on a scale from 1-10, with 1 being no fatigue and 10 being the worst fatigue you have experienced, how fatigued are you at the current time?*'. They did this at 10 am, 3 pm and 8 pm every day for six weeks. Fatigability was measured at baseline and week 6 using the six minute walk test (6MWT) [18]. Participants were asked to walk at their normal, comfortable walking pace back and forth on a measured 16-metre track in a University corridor. Distance walked was measured. At baseline, week 3 and 6 the levels of subjective fatigue experienced over the past seven days were measured using the Neuro-QOL short form questionnaire [19]. The Adult Memory and Information Processing Battery (AMIPB) [20] was used to measure cognitive fatigue. The AMIPB required the second highest number in each row to be

127 circled, with 15 rows of five double digit numbers. Participants had two minutes and their attempts
128 were timed, with incorrect answers being noted.

130 Questionnaires administered at baseline, week 3 and 6 were: the Physical Activity Scale for the
131 Elderly (PASE) [21], EQ5D-5L [22], Preference-Based Multiple Sclerosis Index (PBMSI) [23] and
132 the Hospital Anxiety and Depression Scale (HADS) [24]. Demographic information was collected. A
133 previously published protocol paper gives detail about each measure [25]. Activity was monitored
134 with seven-day wrist worn accelerometers (Axivities ®) prior to, and over two separate weeks of the
135 trial (week 2-3 and 5-6).

137 Blood markers of inflammation were measured including: TNF-alpha, reduced glutathione, a marker
138 of antioxidant status and lipid peroxidation.

140 Detailed description of measures can be found in supplementary file 1.

142 *Process evaluation*

143 Upon exiting the study at week 6, each participant was interviewed about the intervention process,
144 ease of adherence, tolerance and acceptability of the flavonoid drink and the collection of outcome
145 measures. Participants were asked their opinion on the importance of the research question proposed
146 to inform future trials. The thirteen topics used included difficulties with intervention delivery,
147 scheduling of assessments and outcome measure acceptability and suggestions on how to improve the
148 intervention process. A proportion of the data (20%) was coded by two different team members to
149 check on reliability of the coding scheme. Transcripts of interviews were examined to identify themes
150 and categories. Codes were applied to these broad themes, which were then broken down further into
151 sub-codes. Agreement on concepts and coding by blinded assessors were sought between two
152 members of the research team to ensure reliability.

154 *Analysis*

155 Feasibility was analysed through evaluation of eligibility, recruitment and retention [26].
156 Completeness of outcome measures was reported and 80% was set as a criterion for success.
157 Retention was measured by the proportion of participants who were lost to follow-up. Successful
158 adherence to the intervention was defined as at least 75% of the participants having completed cocoa
159 consumption. Further aspects of adherence were measured by the percentage of fatigue texts
160 completed by participants.

161 Primary analysis followed the intention to treat principal utilised the complete case data set.
162 Results were presented using point estimates and 95% confidence intervals. For the fatigue texts the
163 fatigue NRS was calculated as the area under the curve (AUC) for each group, ignoring area beneath

the baseline, and was calculated geometrically [27]. Data was transformed to improve model fit, or different regression approaches were used (e.g. Negative Binomial, or Poisson regression). The results for the 6MWT are reported as mean \pm SD and for the comparison of baseline and post-intervention as mean difference \pm standard error [(SE); 95% (CI)]. A Linear Mixed Model (LMM) was used to differences between groups throughout all time points. Alternatively and wherever the variables were categorical, such as the EQ5D-5L sub categories, a generalized estimating equation (GEE) with appropriate distributions (e.g. Negative Binomial) method was implemented. Both methods used SAS/STAT 14.3. Fatigue and fatigability measures including the Neuro-QoL short form fatigue, the 6MWT and the AMIPB were further analysed to determine difference between responders and non-responders and relative risk scores then calculated. Responders on the NeuroQoL, for both the control and intervention groups, were classified as those who had a clinically meaningful change of 10 points out of 100 (with the questionnaire total score converted from an original total of 40 between baseline and week 6. Responders on the 6MWT were classified as those who had a minimally important change (MIC) in covered distance of 21.6m [27] between baseline and week 6.

Data over three time points for activity data was analysed using a Freidman's test and between group effects were calculated using a Mann-Witney test. Process evaluation included frequencies for adhering to the intervention, session content and progression which was analysed descriptively with confidence intervals and regression where possible. A standard content analysis techniques were employed.

Results

Between May 2016 and August 2017, 40 pwMS were recruited from four neurology clinics including: Oxford University Hospitals NHS Trust (John Radcliffe Hospital site), Milton Keynes hospital, Royal Berkshire hospital or Buckingham hospital or through advertisements and online media (MS Society webpage and MS Trust Facebook page).

Figure 1 shows participant flow. It was not possible to determine the total number of people screened.

Feasibility

Fifty-three people showed an initial interest in the trial, but decided not to take part due to: not having enough time to take part in the trial, did not like chocolate, or were unable to take part in nutrition trials due to being on weight loss programs or having gastric surgery. All but one person consumed the cocoa with rice milk (one consumed almond milk). One person discontinued the control intervention but was not lost to follow up and one person consented to be on the trial but decided not to consume the cocoa from the start of the intervention. Adherence to intervention overall was 100% (19/19) for the intervention group and 90% (19/21) for the control group. Missing data from NRS was less than 20% of total responses, but reporting did drop in week 6. Blood measures were only achieved in 20 participants (after a maximum of three attempts). Overall missing data for secondary measures was less than 20%. There were seven AEs during the trial, caused by worsening fatigue, feelings of nausea, or a general feeling of being unwell. AEs were considered unlikely to be related (five), possibly related but expected/ resolved (one) and not related to the intervention (one). Four AEs were associated with the control cocoa and three with the high flavonoid cocoa. There were no incidences of un-blinding of the researcher nor participant. Five out of 40 people were seen at home at week 3.

Demographic and clinical data are shown in Table 1. There were no significant differences for demographics between the groups at baseline ($p>0.05$).

[Insert Table 1]

Table 1. Demographic information at baseline for both groups

	Intervention (n = 19)	Control (n = 21)
Demographic data		
Age (years)	41 ± 11	46 ± 8
Women	14 (74%)	16 (76%)
BMI (kg/m2)	26 ± 7	25 ± 6
Treatment naïve	7/19(37%)	6/21(29%)
Medications		
Anti-depressants/anxiolytic	6	6
Anti-convalescents/anti-spastics	3	6
Sedating analgesic	0	1
Other sedating	2	7
Other (excluding DMTs)	25	24
Smokers	0(0%)	2(10%)
Uses assistive device	2(11%)	6(29%)
Report food allergy	2(11%)	2(10%)
Reported food intolerance	6(32%)	5(24%)
Reported taking special diet	4(21%)	2(10%)
Fatigue Severity Scale (FSS) Total	5 ± 2	5 ± 3
Barthel Index (BI) Total	20 ± 2	19 ± 8
Physical Activity for the Elderly (PASE) Total	90 ± 32	102 ± 31

Values are means ± standard deviations, or total number of people in () considering the percentage of the total sample population. FSS and Barthel Index totals are reported as medians ± ranges. An independent t-test was used to compare means for age, BMI, PASE. A Mann-Witney U test was used to compare medians for FSS and BI for non-parametric measures to determine differences between the intervention groups. A chi-squared test was used to compare means for nominal data. There were no significant differences between groups for any baseline measures ($p>0.05$).

Outcome measures

Between group effect sizes were considered from all three assessments points. Efficacy potential of fatigue and feasibility was determined. A breakdown of the outcome measures is shown in Table 2.

[Insert Table 2]

Table 2. Results for outcome measures at baseline, week 3 and week 6 of the intervention ^a.

	Control Baseline (n=21)	3 weeks	6 weeks	Intervention Baseline (n=20)	3 weeks	6 weeks	Relative risk c	Effect sizes with 95% CI b
Fatigue								
Neuro-QoL	25.86 ± 1.27	22.55 ± 1.18	22.95 ± 1.51	27.63 ± 0.88	24.21 ± 1.21	22.95 ± 1.17	1.45	0.04 (- 0.40-0.48)
Fatigability								
AMIPB								
Incorrect	1 ± 2	1 ± 1	1 ± 2	0 ± 1	0 ± 1	0 ± 1		-0.13 (- 0.34-0.09)
Time	53.83 ± 3.83	55.80 ± 5.00	52.43 ± 3.44	58.85 ± 4.01	57.66 ± 4.07	58.67 ± 4.74		0.11 (- 0.34-0.55)
6 minute walk	344 ± 17.67	n/a	354.5 ± 19.29	360.9 ± 13.15	n/a	394.6 ± 18.11	1.80	0.45 (0.18 - 1.07)
Numerical rating scale fatigue	n/a	35 + 12	34 + 16	n/a	33 + 18	31 + 18		
QoL								
EQ5D-5L								
Mobility	2 ± 3	2 ± 3	1.5 ± 3	1 ± 2	1 ± 2	1 ± 2		-0.02 (- 0.26-0.22)
Self-care	1 ± 2	1 ± 2	1 ± 2	1 ± 1	1 ± 1	1 ± 1		-0.30 (- 0.43— 0.16)
Usual activities	2 ± 3	2 ± 2	2 ± 3	2 ± 2	2 ± 2	2 ± 2		-0.12 (- 0.33-0.11)
Pain/ discomfort	2 ± 3	2 ± 3	2 ± 3	2 ± 3	2 ± 2	2 ± 3		-0.25 (- 0.45— 0.02)
Anxiety/ depression	1 ± 2	1 ± 2	1 ± 2	2 ± 2	2 ± 2	2 ± 2		0.15 (- 0.07-0.36)
Health today VAS	67.71 ± 3.30	68.50 ± 3.98	74.15 ± 3.56	71.58 ± 3.48	71.95 ± 3.25	72.79 ± 3.30		0.24 (- 0.21-0.69)
HADS								
Depression	5 ± 8	4 ± 7	4.5 ± 9	4 ± 5	5 ± 7	5 ± 7		0.09 (- 0.15-0.33)
Anxiety	7.62± 0.74	7.25± 0.70	6.65± 0.80	7.32± 0.83	7.21± 0.83	6.63± 0.82		0.14 (- 0.31-0.58)
PBMSI								
Walking	2 ± 2	2 ± 2	1.5 ± 2	1 ± 2	1 ± 2	1.5 ± 2		-0.15 (- 0.35-0.07)
Fatigue	2 ± 2	2 ± 2	2 ± 2	2 ± 2	2 ± 2	2 ± 2		-0.12 (- 0.29-0.06)
Mood	1 ± 2	1 ± 2	1 ± 2	1 ± 2	1 ± 2	1 ± 2		-0.10 (- 0.30-0.11)
Concentration	2 ± 3	2 ± 2	2 ± 2	2 ± 2	2 ± 2	2 ± 2		0.05 (- 0.15-0.26)
Roles/ responsibility	1 ± 2	1 ± 2	1 ± 2	1 ± 2	1 ± 1	1 ± 2		-0.06 (- 0.25-0.14)
Mechanism								
Plasma								
Lipid peroxidation	0.66 ± 0.01	0.68 ± 0.01	0.67 ± 0.01	0.69 ± 0.01	0.69 ± 0.01	0.70 ± 0.02		0.50 (0- 0.99)
TNF-alpha	0.12 ± 0.01	0.12 ± 0.01	0.10 ± 0.01	0.13 ± 0.01	0.11 ± 0.01	0.11 ± 0.01		0.01 (- 0.22-0.23)
Glutathione	0.0043 ± 0.0047	0.0045 ± 0.0031	0.0035 ± 0.0030	0.0034 ± 0.0051	0.0035 ± 0.0041	0.0060 ± 0.0040		0.07 (- 0.55-0.69)

a. Vales are means ± SE for normally distributed values and medians ± ranges (1st to 3rd quartile) for categorical data.

b. Effect sizes and CI's are Cohen's d, based on non-central t distributions of least squares means differences for continuous variables, using SAS 9.4 and Cliff's delta, for categorical variables, using R 3.5.

c. Relative risks were calculated for measure of fatigue and fatigability for responders versus non responders.

[Insert Table 3]

Table 3. Physical activity levels (reported in minutes per day on average) using an accelerometer watch prior to the intervention, between 9 to 16 days (3 weeks) into the intervention and between 35 to 42 days (6 weeks) at the end of the intervention, broken down into sedentary light moderate and vigorous classification.

	Baseline control	3 weeks	6 weeks	Baseline interventi on	3 weeks	6 weeks
Activity	1052.97	1031.17	1049.98±1	1049.20	1090.68±	1061.76
Sedentary	± 23.78	±28.07	9.12	± 29.97	32.06	±22.76
Light	302.48 ± 15.15	304.68 ±17.78	305.16 ±14.22	317.59 ±24.28	293.98 ± 23.53	311.70 ± 18.44
Moderate	83.44 ±13.67	101.76 ± 14.29	82.59 ±10.12	71.78±9. 63	76.04±9. 64	82.04±9. .91
Vigorous	1.67 ±0.69	1.65 ±0.82	1.99 ±1.19	1.98 ±0.93	2.74 ±1.05	1.55±0. 49

Vales are means ± SE. Total activity for each participant was broken down into sedentary, light, moderate and vigorous and average for all participants in each group, over each 7-day time period.

Fatigue and fatigability

Fatigue was further analysed to determine difference between responders and non-responders. There was no difference in means between groups ($p>0.05$) yet the Relative Risk (RR) for those who responded and therefore had improved fatigue in the intervention group (11 out of 19 responders) to the control group (8 out of 20 responders) was 1.45. The AMIPB was assessed in a similar way with a change in 1 SD of an improvement in 11.5 seconds considered clinically meaningful. Based on these criteria only one person improved in the intervention group and no one in the control group and therefore a RR was not calculated.

There was a medium effect size for distance walked in six minutes (0.45 {CI 0.18-1.07}) between the groups with the intervention showing a larger increase in the metres walked in 6 minutes after the intervention (Table 2). The RR for responders in the intervention group compared to control was 1.80 in favour of the intervention group.

Process evaluation

Both groups had similar positive experiences about the scheduling of the assessments. 13/19 in the intervention vs 18/20 people in the control indicated no impact of the measurement instruments used on weekly routine over the six weeks. Similar numbers in both groups identified that the outcome measures were acceptable. *Randomisation*: Most comments from both groups indicated acceptance towards the process of randomisation. *Taste*: Similar numbers (8/19 intervention vs 9/20 control) reported positive comments about the taste of the cocoa. *Procedures and routine of preparing the drink*: A few individuals in both groups identified that it was inconvenient to wait for food after drink consumption (4/19 intervention vs 3/20 control), and that the process did not always fit in with their

lifestyle e.g., traveling. Other individuals (15/19 intervention vs 17/20 control) identified that they worked it into a routine. *Continuation of consuming the drink*: half of both groups (9/19 intervention vs 11/20 control) said they would continue the drink if offered. A further four people in both groups said they would continue if it was beneficial or if they could implement their own routine.

Discussion

PwMS engaged with the dietary intervention, with fatigue and fatigability measures responding more in the intervention group with effect sizes calculated. The current study was shown to be feasible and well received by pwMS, with high adherence to the intervention and excellent data completion. Our study establishes that the use of dietary interventions is feasible and may offer possible long-term benefits to support fatigue management, by improving fatigue and walking endurance. We further propose that considering the possible anti-inflammatory mechanism, flavonoids may be used as an adjunctive approach alongside other therapeutic interventions and suggest the possible benefit of such combined approaches for fatigue management. However further full powered trials would need to be performed.

The time post diagnosis was extended from five to ten years in order to recruit to target ($n = 40$). Adherence ($>75\%$), retention and amount of missing data ($<80\%$) were within the acceptable ranges. Most missing data was from the NRS texts over the six weeks which is not surprising as this was the most time-consuming part of the assessment. Completion was still above 80% of total with the first five weeks, with week six showing the most missing data. Mild AEs have previously been reported when consuming high flavonoid cocoa including nausea and vomiting, gastrointestinal disturbances and headaches [28]. The AEs reported in the current trial did not cause any safety concerns and were similar between groups.

This is the first study to suggest the potential for fatigability being improved through a 6MWT after six weeks of a flavonoid intervention, with a moderate effect size. In the current study the intervention showed a MIC over time with 33.7m (SE: 8.4) in contrast to the control group 10.2m (SE: 9.6). Fatigue correlates with a decrease of physical endurance [29] and walking speed [30] and therefore a treatment targeting fatigue could also improve walking performance. Flavonoid have been found to increase cerebral blood flow by inducing widespread stimulation of brain perfusion, and this could also influence mood, cognitive performance, fatigue perception and ability to perform specific movement tasks [31]. When considering other symptoms, pain was shown to improve in the flavonoid group over the six weeks as measured by the EQ5D-5L with a moderate effect size. The antioxidant properties of flavonoids are thought to lessen neuropathic pain by alleviating oxidative stress and thus reducing neuron damage caused by lipid peroxidation. [32]. We did not measure objective measures of pain in this trial and therefore further research is warranted to explore the pain improvement. Indeed previous research has pointed towards higher motivation in physical activity in pwMS when symptoms such as pain were improved [33]. This may also allow pwMS to become more active and mobile, as noted by the improvements on the 6MWT.

The process evaluation revealed that overall the trial was well accepted, with the timing of assessments and the outcome measures being convenient and low burden, respectively and the participants in both groups found the taste of the cocoa enjoyable, or noted it as neither tasty nor unacceptable. In both groups the blinding and randomisation process were accepted, and a majority of

pwMS in both groups declared their willingness to continue consuming the cocoa long term, especially if benefits to fatigue were found. However findings around the preparation of the drink and/or scheduling the timing of drink consumption into ones routine are factors to consider for future trials.

Limitations

As a feasibility study a powered investigation using a sample size of 80 is now needed. For blood measures, the lack of ability of the phlebotomist to collect blood from several of the participants led to missing data. From the data collected, there were small effect sizes in blood indicators, apart from lipid peroxidation which showed a moderate effect size and therefore this area needs further investigation. The NRS fatigue data was analysed as a total whole change over the six weeks, and therefore more sensitive analysis may have discovered changes within the six weeks. Fatigue may be both physical and cognitive and coexists with and is impacted by a number of factors including anxiety and depression. This study measured a number of these factors including: motor (6MWT) and cognitive (AMIPB) fatigue, and anxiety and depression (HADS) which could be further investigated in a study powered for this. In this pilot we set out to reduce variability from these factors where possible, for example we excluded individuals with a clinical diagnosis or receiving treatment for depression (such as individuals on antidepressants)

It should be considered that, while we used a wide range of recruitment methods reducing the risk of recruitment bias, participants were recruited from affluent areas of the UK. Acknowledging this limitation, we nevertheless propose the responses in outcome measures are largely generalizable to relatively healthy pwMS.

Conclusion

The use of dietary approaches to reduce fatigue and associated factors in pwMS may be an easy, safe and cost effective way to impact on quality of life and independence, allowing people to feel more in control of their condition. A full evaluation including wider geography, longer follow up and cost effectiveness is now indicated. This technology has the potential to be implemented in the UK and worldwide, and alongside other rehabilitation including exercise, DMTs and physiotherapy.

Figure 1 Flow of recruitment legend: The screening and enrolment process for a 6 week randomised double-blind placebo-controlled feasibility trial in people with Multiple Sclerosis. A total of 40 people were included in the final analysis, and reasons for not receiving the allocated intervention (cocoa drink) and discontinuation are presented.

418 *Contributorship*

419 Coe, Collett, Soundy, Clegg, Cavey, Wade, Palace, De Luca, Harrison, Buckingham and Dawes were
420 involved in the design and ongoing conduct of the project.

421 Coes and Dawes were responsible for the overall conduct of the project.

422 Coe, Cossington, Soundy, Durkin, Kirsten, and Dawes were responsible for the data collection and
423 day to day running of the trial.

424 Izadi was involved in the statistical analysis of the project.

425 All authors were involved in the writing and proof reading of the project.

426 Wade was responsible for AEs.

427

428 *Trial sponsorship*

429 Oxford Brookes University

430

431 *Funding*

432 Funding for the trial was granted from the Multiple Sclerosis Society; Grant reference 32.

433 Dawes is funded by Elizabeth Casson Trust and Higher Education Thames Valley and the Biomedical
434 Research Centres. Collett is funded by Heath Education Thames Valley.

435 Disclosure funding for highly specialised services to run a national congenital myasthenia service and
436 a neuromyelitis service. Support for scientific meetings and honorariums for advisory work from
437 Merck Serono, Biogen Idec, Novartis, Teva, Abide, Chugai Pharma, Alexion, MedDay, Argenx and
438 Bayer Schering, Medimmune and unrestricted grants from Merck Serono, Novartis, Biogen Idec,
439 Chugai, Alexion and Bayer Schering. MS society and Guthrie Jackson Foundation research grants.

440

441 *Conflict of interest*

442 There was no conflict of interest

443

444 *Ethical approval*

445 Ethical approval was granted from the National Research Ethics Service {Solihull West Midlands}
446 reference: 199515)

References

1. Strober, L.B., *Fatigue in multiple sclerosis: a look at the role of poor sleep*. Front Neurol, 2015. **6**: p. 21.
2. Wolkorte, R., D.J. Heersema, and I. Zijdewind, *Muscle Fatigability During a Sustained Index Finger Abduction and Depression Scores Are Associated With Perceived Fatigue in Patients With Relapsing-Remitting Multiple Sclerosis*. Neurorehabil Neural Repair, 2015. **29**(8): p. 796-802.
3. Kluger, B.M., L.B. Krupp, and R.M. Enoka, *Fatigue and fatigability in neurologic illnesses: proposal for a unified taxonomy*. Neurology, 2013. **80**(4): p. 409-16.
4. Srinivasan, R., et al., *Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T*. Brain, 2005. **128**(Pt 5): p. 1016-25.
5. Asano, M. and M.L. Finlayson, *Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: exercise, education, and medication*. Mult Scler Int, 2014. **2014**: p. 798285.
6. Langeskov-Christensen, M., et al., *Potential pathophysiological pathways that can explain the positive effects of exercise on fatigue in multiple sclerosis: A scoping review*. J Neurol Sci, 2017. **373**: p. 307-320.
7. Schwarz, S., et al., *Complementary and alternative medicine for multiple sclerosis*. Mult Scler, 2008. **14**(8): p. 1113-9.
8. Sathyapalan, T., et al., *High cocoa polyphenol rich chocolate may reduce the burden of the symptoms in chronic fatigue syndrome*. Nutr J, 2010. **9**: p. 55.
9. Sathyapalan T, C.P., Beckett S, Rigby AS & Atkin SL, *High cocoa polyphenol rich chocolate improves the symptoms of chronic fatigue*. Endocrine Abs, 2006. **6**.
10. Coe, S., et al., *Flavonoid rich dark cocoa may improve fatigue in people with multiple sclerosis, yet has no effect on glycaemic response: An exploratory trial*. Clin Nutr ESPEN, 2017. **21**: p. 20-25.
11. Hedstrom, A.K., et al., *High consumption of coffee is associated with decreased multiple sclerosis risk; results from two independent studies*. J Neurol Neurosurg Psychiatry, 2016. **87**(5): p. 454-60.
12. Azary, S., et al., *Contribution of dietary intake to relapse rate in early paediatric multiple sclerosis*. J Neurol Neurosurg Psychiatry, 2018. **89**(1): p. 28-33.
13. Weiland, T.J., et al., *Clinically significant fatigue: prevalence and associated factors in an international sample of adults with multiple sclerosis recruited via the internet*. PLoS One, 2015. **10**(2): p. e0115541.
14. Bisht, B., et al., *A multimodal intervention for patients with secondary progressive multiple sclerosis: feasibility and effect on fatigue*. J Altern Complement Med, 2014. **20**(5): p. 347-55.
15. Yadav, V., L. Shinto, and D. Bourdette, *Complementary and alternative medicine for the treatment of multiple sclerosis*. Expert Rev Clin Immunol, 2010. **6**(3): p. 381-95.
16. Herlofson, K., et al., *Fatigue in early Parkinson's disease. Minor inconvenience or major distress?* Eur J Neurol, 2012. **19**(7): p. 963-8.
17. Kurtzke, J.F., *Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)*. Neurology, 1983. **33**(11): p. 1444-52.
18. Goldman, M.D., R.A. Marrie, and J.A. Cohen, *Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls*. Mult Scler, 2008. **14**(3): p. 383-90.
19. Cella, D., et al., *Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology*. Neurology, 2012. **78**(23): p. 1860-7.

20. Vlaar, A.M. and D.T. Wade, *The Adult Memory and Information Processing Battery (AMIPB) test of information-processing speed: a study of its reliability and feasibility in patients with multiple sclerosis*. Clin Rehabil, 2003. **17**(4): p. 386-93.
21. Washburn, R.A., et al., *The Physical Activity Scale for the Elderly (PASE): development and evaluation*. J Clin Epidemiol, 1993. **46**(2): p. 153-62.
22. Herdman, M., et al., *Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)*. Qual Life Res, 2011. **20**(10): p. 1727-36.
23. Kuspinar, A., et al., *Using existing data to identify candidate items for a health state classification system in multiple sclerosis*. Qual Life Res, 2014. **23**(5): p. 1445-57.
24. Zigmond, A.S. and R.P. Snaith, *The hospital anxiety and depression scale*. Acta Psychiatr Scand, 1983. **67**(6): p. 361-70.
25. Coe, S., et al., *A protocol for a randomised double-blind placebo-controlled feasibility study to determine whether the daily consumption of flavonoid-rich pure cocoa has the potential to reduce fatigue in people with relapsing and remitting multiple sclerosis (RRMS)*. Pilot Feasibility Stud, 2018. **4**: p. 35.
26. Craig, P., *A new CONSORT extension should improve the reporting of randomized pilot and feasibility trials*. J Clin Epidemiol, 2017. **84**: p. 30-32.
27. Cella, M. and T. Chalder, *Measuring fatigue in clinical and community settings*. J Psychosom Res, 2010. **69**(1): p. 17-22.
28. Crews, W.D., Jr., D.W. Harrison, and J.W. Wright, *A double-blind, placebo-controlled, randomized trial of the effects of dark chocolate and cocoa on variables associated with neuropsychological functioning and cardiovascular health: clinical findings from a sample of healthy, cognitively intact older adults*. Am J Clin Nutr, 2008. **87**(4): p. 872-80.
29. CRE-2008-0419, *Test-retest Reliability of the StepWatch Activity Monitor Outputs in Individuals with Chronic Stroke measure*. Clinical Rehabilitation, 2008.
30. Huisinga, J.M., et al., *Is there a relationship between fatigue questionnaires and gait mechanics in persons with multiple sclerosis?* Arch Phys Med Rehabil, 2011. **92**(10): p. 1594-601.
31. Nehlig, A., *The neuroprotective effects of cocoa flavanol and its influence on cognitive performance*. Br J Clin Pharmacol, 2013. **75**(3): p. 716-27.
32. Azevedo, M.I., et al., *The antioxidant effects of the flavonoids rutin and quercetin inhibit oxaliplatin-induced chronic painful peripheral neuropathy*. Mol Pain, 2013. **9**: p. 53.
33. Fragoso, Y., Santana, DLB, Pinto, RC, *The positive effects of a physical activity program for multiple sclerosis patients with fatigue* Neurorehabilitation, 2008. **23**(2): p. 153-57.